Pharmacokinetics of pioglitazone after multiple oral dose administration in horses.

The study focused on observing how a diabetes medication known as pioglitazone behaves in the body of horses when given multiple times. The authors found that when given at a regular daily dose over the course of a set period, the concentrations achieved in the blood were similar, but slightly lower, to the levels considered effective in humans.

Objective of the Study

• The goal of this research was to scrutinize the pharmacokinetics – how the drug moves within the body – of pioglitazone in adult horses after it’s administered several times orally. Pioglitazone is an antidiabetic medication that has shown to improve insulin sensitivity in human patients with noninsulin-dependent diabetes mellitus, a condition comparable to equine metabolic syndrome.

Procedures in the Study

• The experiment commenced with a pioglitazone hydrochloride (1 mg/kg) pilot study conducted on one horse. Following this, the drug was given to an additional six horses, 11 doses at 24-hour intervals each. The researchers collected plasma samples to enable further analysis.
• The blood samples were examined using a technique named liquid chromatography coupled with tandem mass spectrometry to measure the amount of drug in the plasma. The data collected from this process was then used for pharmacokinetic modeling.

Results of the Study

• The peak plasma concentration (the highest level of the drug in the bloodstream) was achieved approximately 2 hours after the administration of the first dose of pioglitazone, with a slight increase in time for the 11th dose.
• The apparent elimination half-life – the time required for the concentration of the drug in the body to decrease by half – was about 10 hours, regardless of the first or eleventh dose. This indicates steady-state of the drug was achieved.”
• Overall, consistent once-daily oral dosing of pioglitazone resulted in plasma concentrations and total drug exposure in these healthy horses that almost match – albeit slightly below – the levels generally regarded as therapeutic (or beneficial) in humans.

Implications of the Study

• This study has important implications for the use of pioglitazone in horses, particularly those with conditions similar to human noninsulin-dependent diabetes mellitus. It implies that pioglitazone might be an effective treatment for such horses, offering a potential new avenue for veterinary medicine.
• However, it’s crucial to consider that the plasma concentrations achieved in horses in this study were slightly lower than what’s deemed therapeutic in humans. Therefore, further research may be required to establish the optimal dosing regimen and efficacy in horses, to fully realize the potential benefits of this medication in the equine population.